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Introduction  
     There are multiple inhibition targets and inhibitors of the 
Human Immunodeficiency Virus (HIV) highlighting the 
challenge posed by this constantly evolving disease.1 The ability 
of the virus to mutate and maintain function is key to its 
continued virulence. This has resulted in over 25 million 
Acquired Immune Deficiency Syndrome (AIDS) related deaths 
worldwide; with over 34 million people currently suffering from 
the HIV.2 
    The domestic cat is an effective non-primate animal model for 
lentivirus infections.3 The feline model is the smallest natural 
host for a lentiviral infection with an acute phase and a variable 
latent phase.3b Feline Immunodeficiency Virus (FIV) has an 
analogous AIDS type progression with neurological involvement 
and selective CD4+ lymphocyte depletion.4 FIV was the first 
lentivirus to demonstrate resistance,5 which is a key obstacle in 
the effective treatment of HIV.6 One way to combat this issue 
would be to target mutation resistant proteins at the core of the 
viral replication cycle. The double zinc finger nucleocapsid 
protein (NCp) fits this profile, with involvement at multiple 
points of the viral replication cycle where deletion or 
modification of either zinc finger leads to virus inactivation.7 
 
* Corresponding authors. E-mail address: chris.asquith@unc.edu  
(C. R. M. Asquith) and s.hilton@ucl.ac.uk (S.T. Hilton). 
     The NCp has multiple roles within the viral replication cycle 
including packing, dimerization, organization of the protein-RNA 
complexes within the newly created virons and annealing of the 
cellular primer tRNA3lys to the primer binding site in reverse 
transcriptase.7 The NCp double zinc finger peptide unit C-X2-C-
X4-H-X4-C (CCHC) is conserved across almost all retroviruses 
including HIV-1/2, FIV, Simian Immunodeficiency Virus (SIV), 
Equine Infectious Anemia Virus (EIAV) and others.8 
     Despite the promising potential of targeting the NCp there are 
currently no clinically approved small molecule inhibitors.9-10  
While there have been several recent examples of protein binders 
to the nucleic acid binding cleft between the two zinc fingers 
with some encouraging results none have progressed to the 
clinic.11 However, there are two high profile zinc ejectors that 
have been used clinically. The first, was azodicarbonamide 
(ADA) - 1 an anti-viral zinc ejector progressed to phase 1/2 
clinical trials but was later withdrawn.12 The other was a 
benzisothiazolone (BITA) - 2 zinc ejector that also failed to reach 
the progression milestones.13 These are part of a wider suite of 
compounds that have been shown to be activity via zinc ejection 
(Figure 1). These include the original zinc ejectors 3-
nitrosobenzamide (NOBA) - 3 and 2,2’-di-thiobisbenzamide 
(DIBA) - 4, with more recent examples including 2,2-
diselenobisbenzamides (DISeBAs) - 5 and pyridinioalkanoyl 
thiolesters (PATES) - 6 among others.12-14 
ART ICLE  INFO  AB ST R ACT  
Article history: 
Received 
Received in revised form 
Accepted 
Available online 
Focused libraries of multi-substituted epidithiodiketopiperazines (ETP) were prepared and 
evaluated for efficacy of inhibiting the nucleocapsid protein function of the Feline 
Immunodeficiency Virus (FIV) as a model for HIV. This activity was compared and contrasted 
to observed toxicity utilizing an in-vitro cell culture approach. This resulted in the identification 
of several promising lead compounds with nanomolar potency in cells with low toxicity and a 
promising therapeutic index. 
2019 Elsevier Ltd. All rights reserved. 
 
Keywords: 
Epidithiodiketopiperazines (ETP) 
Zinc ejection  
Feline Immunodeficiency Virus (FIV)  
Human Immunodeficiency Virus (HIV) 
Nucleocapsid protein (NCp) 
 
 
Figure 1. Examples of some significant previously reported zinc ejectors 
 
     The zinc ejection mechanism has demonstrated potential on a 
number of biological applications including metallothionein for 
oxidative stress,15 transcription factors involved in viral 
replication16 and inhibition of histone lysine demethylase 
JMJD2A.17 The HIF-1 alpha/P300 interaction triple zinc finger 
has also been effectively targeted with a number of different 
chemotypes.18 One of these chemotypes is the 
epidithiodiketopiperazine (ETP) which has a known internal 
redox chemistry and an ability to coordinate zinc.18a,19 
     A diverse portfolio of biological activities including anti-viral, 
anti-bacterial and immunomodulation have been demonstrated by 
the ETP class of compound. This has resulted in the ETP core 
being the focus of many synthetic efforts and structural 
elucidations (6-14).20 The ETP natural products (Figure 1) have 
historically been difficult to synthesize due to the complex 
structure and the sensitivity of the disulfide bond.20 
Results and Discussion  
     Most reported synthetic approaches towards the ETP core 
have relied on formation of the diketopiperazine ring prior to 
addition of sulfur either via displacement of a leaving group, or 
addition of sulfur to an intermediate iminium ion.21,20q,20y Recent 
approaches have shown that simple ETP derivatives can be 
obtained by reaction of the diketopiperazine ring with sulfur or 
sulfur electrophiles under basic conditions.22,20k We utilized a 
hybrid approach where the diketopiperazine ring is formed at the 
same time as sulfur is incorporated (Scheme 1).23 This reduced 
the overall number of steps required to access the ETP core and 
mitigated some of the functionality issues associated with late 
stage addition of sulfur. 
    First benzylamine (15) or methylamine (16) was added to a 
solution of ethyl glyoxalate in toluene, followed by the addition 
of p-methoxybenzylmercaptan to form 17 and 18 using the Dean 
and Stark method, in high yield.  This was followed by coupling 
of 2-chloro-2-oxoethane-1,1-diyl diacetate to form diacetate 
intermediates 19 and 20.23a The cyclisation precursor 19 and 20 
were then treated with p-methoxybenzylmercaptan and the 
corresponding amine (Table 1) with a 4-dimethylaminopyridine 
(DMAP) catalysis to produce 21-32 which were set up in the 
correct orientation to form the disulfide bridge motif. The p-
methoxybenzyl (PMB) protecting groups were cleaved with 
boron tribromide at -78 oC, before being warmed and treated with 
iodine to furnish the final ETP core 33-44 in good to excellent 
yields (Scheme 1). 
     The compounds (33-44) were initially tested at three higher 
concentrations (100, 10 & 1 μM) in a MTT cell viability assay 
over 24 hours using Crandell Rees Feline Kidney (CrFK) cells as 
a measurement of acute toxcity.24,25 These initial results 
highlighted compounds that were acutely toxic (Table 1). The 
compounds (33-44) were then tested for anti-viral capabilities 
against FIV using an IL-2 independent feline lymphoblastoid 
(FL-4) cell at six concentrations (100 μM - 1 nM) over a period 
of seven days.25,26 These chronically infected FL-4 cells were 
exposed to 33-44 over a period of seven days and sampled every 
day at each of six concentrations to determine the extent of viral 
replication/viral suppression.25 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Examples of ETP containing natural products 
Scheme 1. Synthesis route to dimeric ETP derivatives - reagents and 
conditions (a) ethyl glyoxalate, p-methoxybenzylmercaptan, toluene, 2 h, 17 - 
37 %, 18 - 87 %; (b) 2-chloro-2-oxoethane-1,1-diyl diacetate, NaHCO3, 
CH2Cl2/H2O, 12 h, 19 - 97 %, 20 - 95 %; (c) p-methoxybenzylmercaptan, R
2-
NH2, DMAP, MeCN, 16 h, 21 - 62 %, 22 - 33 %, 23 - 65 %, 24 - 64 %, 25 - 
54 %, 26 - 64 %, 27 - 68 %, 28 - 84 %, 29 - 61 %, 30 - 76 %, 31 - 70 %, 32 - 
58 %; (d) 1. BBr3, CH2Cl2, -78 °C 0.3 h, 2. I2, RT, 0.5 h, 33-44 - 32-85 %. 
     Viral RNA was isolated from cell culture supernatants using 
the MagNA Pure LC System with the Total Nucleic Acid 
Isolation Kit (Roche Applied Science, Switzerland). Quantitative 
real-time reverse transcription polymerase chain reaction (RT-
qPCR) was used to determine viral loads.27 The remaining FL-4 
cells were then subjected to a MTT cell viability assay to validate 
the RT-qPCR result, confirming it was not caused by non-
specific toxicity and to provide a therapeutic index (Table 1). The 
toxicity and activity of azidothymidine (AZT) and Raltegravir 
were consistent with previous reports on FIV/HIV and were used 
as an internal standard and benchmark (Table 1).28,29 
     The limited toxicity observed in the initial screening with CrFK 
cells with 24-hours exposure may be a good indication that the 
compounds are not chronically toxic. However, there was 
increased toxicity with shorter chained substitutions (33 & 35-
37). There was roughly an order of magnitude increase in toxicity 
when looking at the results for the longer-term FL-4 assay, which 
is consistent with previous results from this model.25 The overall 
toxicity profile of the compounds (33-44) is encouraging as the 
ETP core is generally correlated to acute cytotoxicity. The results 
from prolonged exposure are particularly striking, as there was  
limited toxicity particularly for bulkier substitutions (39-44) and 
compounds that have functional groups that would assist with 
solubility, such as an ester (41-43). This likely enhancement in 
solubility is supported by the significantly lower melting points 
(<100 oC) of 41-43 compared to compound 33 (>200 oC).30 
     Poor solubility may have been a contributing factor to the 
weaker anti-viral efficacy of compound 33 and negligible 
therapeutic index. The addition of a benzyl group (34) did assist 
in increasing the potency 3-fold while not compromising the 
toxicity profile. Changing the methyl substituent to a n-butyl (35) 
also gave a slight boost in potency and an increase in cLogP, 
however the iso-propyl (36) and allyl (37) showed a decreased 
potency with respect to 35. The di-substituted benzyl (38) 
showed the worst performance with the weakest potency of any 
analogue tested from this series and a 6-fold drop of compared 
with 35, this could be in part due to an inability to cross the cell 
membrane. In stark contrast the 3-chloro substitution (39) 
showed an 8-fold increase in potency and a triple digit 
therapeutic index. The p-methoxybenzyl (40) demonstrated a 
slight increase in potency but a significant jump in toxicity 
brought the therapeutic index down to 57 from 184. However, the 
switch to an ester containing motif brought potency down to 
double digit nanomolar for compounds 41 and 42 with a 
therapeutic index above 300 for 42. Compound 43 also 
performed well, but increased toxicity suppressed the therapeutic 
index. The naphthalene substitution (44) suffered the same fate as 
38 with a decrease in potency and therapeutic index. 
 
 
Table 1. Results of FIV and cytotoxicity screening on dimeric ETP derivatives  
 
 
 
 
Compound Residue CrFKa  CC50
b  EC50
b TI clogPc 
Number R1 R2 %  µM µM     
33 Me Me 77 >10 3 >3 0.61 
34 benzyl Me >100 >10 0.91 >11 2.21 
35 benzyl n-butyl  63 >10 0.63 >16 3.8 
36 benzyl iso-propyl  50 6.5 1.6 4 3.05 
37 benzyl allyl 96 5.1 2.1 2.4 2.99 
38 benzyl benzyl >100 4.7 4 1.2 3.71 
39 benzyl (3-chloro)benzyl >100 >100 0.55 >184 4.43 
40 benzyl (4-methoxy)benzyl 99 5.4 0.41 57 3.63 
41 benzyl ethyl 3-propanoate >100 >10 0.053 >190 3.22 
42 benzyl methyl 3-hexanoate >100 >10 0.034 >300 3.29 
43 benzyl ethyl 3-butanoate >100 7.5 0.16 48 3.41 
44 benzyl (methyl)napthalene >100 7.2 1.9 4 4.89 
- AZT >100 >100 5.3 19 -0.16 
- Raltegravir >100 >100 0.01 >10000 1.16 
aSample concentration of compound in CrFK cells at 10 μM (% Viability); bGeometric mean, each concentration tested in triplicate after 7 days as a 
difference of the untreated cells; cCalculated using Chemdraw Ultra 16
  
     In order to better understand the mechanics behind the 
possible mechanism of action we simulated the generalized 
ETP core to attempt to rationalize the results we observed 
(Figure 3). We visualized a combination of Jaguar minimized 
models showing HOMO orbital of one cysteine tooth 
(blue/red)31 and single point fukui f- negative field 
(white/green) calculation for compound 42 and 34. This 
demonstrated a propensity for a favorable reaction on the S-S 
of the ETP core structure (Figure 3A-C). 
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Figure 3. Visualization of negative components of condensed Fukui f- 
functions of with two isovalues 0.01 (white) and 0.002 (green). Minor 
Fukui f- surfaces are omitted for clarity: (a) negative Fukui F-functions of 
42; (b) negative fukui functions of 34; (c) Simulation of 34 potential initial 
stage of the zinc ejection mechanism with the NCp CCHC zinc finger 
active site where Fukui f- functions are shown with two isovalues 0.01 
(white) and 0.002 (green). In addition, HOMO-orbitals taken from Zinc 
finger model are shown. 
 
 
     We calculated the HOMO and LUMO orbitals of a 
simplified disubstituted epidithiodiketopiperazines ETP using 
density functional theory (DFT) and estimated the relative 
reactivity from atomic Fukui indices derived from frontier 
orbital theory (Figure 4).32 Most reactivity of the core resided 
on the disulfide bridge, with substitutions appearing to only 
have a limited effect. 
 
A    B  C   
D E       F  
 
Figure 4. Investigation of reactive bond orbitals for cmpd 34 and general 
ETP cores (a) 2D representation of cmpd 34; (b) HOMO orbital calculation 
for cmpd 34 (c) visual representation of HOMO orbital for cmpd 34; (d) 3D 
representation of cmpd 34; (e) LUMO orbital calculation for cmpd 34; (f) 
visual representation of LUMO orbital for cmpd 34. 
 
     The HOMO-LUMO gap for compound 34 is relatively small 
indicating why the compounds are stable in the ground state 
and not readily decomposing despite the ring strain (Figure 4). 
However, the ability of 34 to accept a nucleophilic attack 
appears more related to the puckered nature of the S-S bond 
(Figure 4D). The LUMO orbitals indicate that the S-S bond 
bridge can accept electrons, following to reorganisation 
effectively after bond dissociation. The S-S bond bridge is a 
key feature of the ETP core and sits above the rest of the 
structure. 
We also wanted to investigate the conformation of the 
disubstituted ETP core and found the crystal structures of 
compounds 36, 40, 41 and 44 all crystallized in the monoclinic 
P21/n space group (Figure 5).
33 The conformations of the ETP 
cores of all four molecules are virtually identical within the 
crystal structures and all bond lengths and angles do not deviate 
significantly from standard values in comparison with 
equivalent bond lengths and angles in the CSD.34 
 
A                      B 
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Figure 5. Crystal structure of compound 36, 40, 41 & 44 showing bridged 
disulfide 
 
     During our investigation of the binding dynamics of the ETP 
structure we also observed through molecular docking using 
standard SP and qm-polarized docking, there was an overall 
poor convergence on target when orentating the structure to be 
set up for nucleophilic attack. This suggested that zinc 
abstraction, although driven mainly by disulfide bridge 
functionality does have an inital docking pose. The intial 
interaction begins with the coordination of carbonyl to zinc, 
where subsequently the sulfur atoms are close to solvent 
exposed cysteines. Watermap analysis utilising the Schrodinger 
suite confirmed placement of a water next to zinc supporting 
this hypothesis (Figure 6A).35  
A                      B 
 
Figure 6. WaterMap analysis and docking (a) Confirmation of favourable 
water placement (-9.3 kcal/mol) (green ball showed placement of stable 
water molecule with red interaction field showing high free energy density. 
(b) grid type of MOE interaction potential for carbonyl oxygen of 34 (red 
grid field). MOE gives estimates of HB strengths shown with blue labels 
and selected distances in magenta.  
This water can be usurped by the carbonyl of the ETP core 
structure. This observation is supported by interaction field 
analysis (MOE 2018.01, Chemical Computing Group) which 
placed the carbonyl in a favorable binding mode (Figure 6B). 
We also investigated the conformation of the ETP core to 
examine the multi-substituted version of the ETP structure to 
see if perturbations near the carbonyl/disulphide would assist in 
increasing the overall anti-viral effect of the compounds. In 
order to achieve this, we designed and synthesized multi-
substituent ETP analogs with small substituents next to the 
carbonyl and disulphide bridge.  
In order to access trisubstituted ETPs a similar approach 
when forming the di-substituted products (33-44) were used 
first forming ethyl 2-(allylamino)-2-((4-
methoxybenzyl)thio)acetate (46) or 17 using allylamine (45) or 
15 respectively under Dean and Stark conditions with ethyl 
glyoxalate and p-methoxybenzylmercaptan. The cyclisation 
diacetate precursor was formed by coupling 2-chloro-2-
oxoethane-1,1-diyl diacetate to 46 and 17 to form 47 and 18. 
These cyclisation intermediates (47) and 19 were treated with 
15 or 45 to undergo a base catalysed cyclisation using DMAP 
and methanol to afford 48-51 in each of the corresponding 
substitution patterns. This enabled the access to a small tri-
substituted array of analogs via treatment with lithium 
bis(trimethylsilyl)amide then an alkyl bromide in THF to afford 
(52-56). This step was achieved in good yields (49-78%), 
which enabled unmasking of the methoxy group with treatment 
of 52-56 with TFA and p-methoxybenzylmercaptan to afford 
the masked ETP precursors (57-61). These were treated with 
boron tribromide at -78oC to unmask the thiol before oxidation 
with iodine to afford the final tri-substituted ETP products (62-
65) in good overall yields (21-28%). 
To access the tetra-substituted allyl analog, 61 was treated 
with lithium bis(trimethylsilyl)amide then an alkyl bromide in 
THF to afford 66. The precursor 66 was then unmasked with 
boron tribromide at -78oC and subsequently treated with iodine 
to afford the final ETP product in the array 67. 
     Utilising the same screening cascade as before, we tested 6-
8, 62-65 and 67 for anti-viral efficacy and cytotoxicity (Table 
2). The natural products 6-8 were particularly toxic. 
Compounds 6 and 7 were not screened in the anti-viral assay as 
8 highlighted a connection between the acute toxicity and 
perceived anti-viral effect. Fortunately, we observed only 
limited toxicity with our multi-substituted ETP analogs 62-65 
and 67. Benchmarking these compounds to the disubstituted 
compounds 37 and 38. Walking the allyl group around the 
dibenzyl ETP core significantly increased the anti-viral potency 
without increasing toxicity. Compound 62 demonstrated a 4-
fold improvement in anti-viral efficacy with a significant 
improvement in the toxicity ratio with a therapeutic index about 
80. 63 showed a 10-fold increase in potency, with a similar 
therapeutic index. 64 with the allyl now switched to the amino 
substitution showed an 8-fold increase toxicity with no 
improvement in anti-viral activity reducing the effective 
therapeutic window to below 10. 65 had poor aqueous 
solubility, likely accounting for lack of an activity profile. 67 
has a similar anti-viral potency to 62, highlighting the 
importance of the pendent benzyl substituents over the simple 
allyl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis route to tri- and quad-meric ETP derivatives - 
reagents and conditions (a) ethyl glyoxalate, p-methoxybenzylmercaptan, 
toluene, 2h, 46 - 37%; (b) 2-chloro-2-oxoethane-1,1-diyl diacetate, 
NaHCO3, CH2Cl2/H2O, 12 h, 47 - 95 %; (c) R
2-NH2, DMAP, MeOH, 5 h, 
48 - 79%, 49 -  72%, 50 - 76% and 51 - 85%;  (d) R3-Br, LiHMDS, THF, 
2.5 h, 52 - 49%, 53 - 79%, 54 - 78%, 55 - 68% and 56 - 65 %; (e) p-
methoxybenzylmercaptan, TFA, CH2Cl2, 18 h, 57 - 81%, 58 - 83%, 59 - 
82%, 60 - 78% and 61 - 63%; (f) 1. BBr3, CH2Cl2, -78 °C 0.3 h, 2. I2, RT, 
0.5h, 62 - 23%, 63 - 24%, 64 - 21 % and 65 - 28%; (g) R4-Br, LiHMDS, 
THF, 2.5h, 66 - 55%; (h) 1. BBr3, CH2Cl2, -78 °C 0.3 h, 2. I2, RT, 0.5 h, 67 
- 41%. 
 
     The modelling of the Fukui indices of 63 (Figure 7 and 8), 
highlights the reactive potential of the ETP disulphide bridge. 
These values are consistent with previous reports,25 and indicate 
that these compounds are available for nucleophilic attack and 
redox chemistry (Figure 9). 
 
 
 
 
 
 
 
A                         B 
Figure 7. f_NN for 63 (a) LUMO indicates (b) HOMO indicates, 
highlighting the reactivity on the central ETP disulfide bridge. 
 
 Table 2. Results of FIV and cytotoxicity screening  
 
 
 
 
 
Compound Residue CrFKa CC50
b EC50
b TI clogPc 
Number R1 R2 R3 R4 % Viability  µM µM     
6 - - - - 6.1 - - - -0.03 
8 - - - - 11 0.0035 0.0017 2.1 1.21 
7 N-Me N-Me N-benzyl N-methanol 74 - - - 1.91 
37 N-benzyl N-allyl - - 96 5.1 2.1 2.4 2.99 
38 N-benzyl N-benzyl - - >100 4.7 3.9 1.2 3.71 
62 N-benzyl N-allyl N-benzyl - >100 79 0.89 88 4.92 
63 N-benzyl N-benzyl N-allyl - >100 6.0 0.088 69 4.92 
64 N-allyl N-benzyl N-benzyl - 85 0.72 0.11 6.7 4.92 
65 N-allyl N-benzyl N-allyl - >100 >100 >10 - 4.08 
67 N-allyl N-allyl N-allyl N-allyl 99 8.8 0.88 10 4.34 
aSample concentration of compound in CrFK cells at 10 μM (% Viability); bGeometric mean, each concentration tested in triplicate after 7 days as a difference of 
the untreated cells; cCalculated using Chemdraw Ultra 16 
 
Figure 8. Visualization of negative values of Fuikui f- functions with two 
isovalues 0.01 (green) and 0.003 (white) are shown. Simulation of 63 at the 
potential initial stage of the zinc ejection mechanism with the NCp CCHC 
zinc finger active site where Fukui f- functions are shown with two isovalues 
0.01 (white) and 0.002 (green). In addition, HOMO-orbitals taken from Zinc 
finger model are shown.  
Our proposed mechanism of action for the ETP core is consistent 
with previous reports, with the zinc-binding sites on the NCp of 
FIV which we determined using DFT calculations (Figure 4). 
The zinc ejection mechanism has previously been characterized 
with NMR and MS studies on HIV NCp7 and other targets, with 
an observable formation of protein-zinc-thiol(ate) complexes and 
several covalent modifications (Figure 9).36,18a We reasoned that 
ETP core mediated zinc ion ejection also occurs via an analogous 
FIV system in a similar mechanism to known zinc 
binding/disrupting compounds in which a zinc-binding cysteinyl 
thiol(ate) reacts with the disulfide of the core to generate a 
transient protein-ETP disulfide (Figure 9). This can rearrange to 
form an intramolecular protein disulfide with consequent 
reduction in zinc ion affinity. The ejected zinc ion (or zinc ETP 
core complex) could then complexes with a second (reduced) 
ETP core to form a stable complex which is analogous to work 
previously reported on the ETP class of natural products and 
some synthetic analogues.18a 
 
 
 
 
Figure 9. Proposed mechanism of action of the generalized ETP core for 
modification of NCp A - summary of the mechanism of zinc ejection from 
NCp/NCp7. B - a Zn2+-coordinating cysteine thiol(ate) reacts with the 
disulfide of the ETP core to generate a transient intermediate disulfide. The 
disulfide then rearranges to form an intramolecular protein disulfide with 
consequent reduction in zinc ion affinity. The ejected zinc ion (or part Zn2+ 
complex) can then complex with a second ETP core (reduced) to form a 
stable complex. 
 
To further support the observed activity and proposed 
mechanism of action we sought to show that disrupted disulfides 
were less active. The focus of this work builds on the idea that 
the disulphide bridge is pivotal to the activity of the compounds 
against the NCp target. We synthesized two disrupted disulfides 
on a simple dibenzyl scaffold (Scheme 3). The first was 
produced from glycine anhydride (68) over 4 steps to produce the 
dithiol version of the dibenzyl ETP (69) from literature 
precedent.18a The second derivative was made by reducing the 
disulphide bridge of 38 with sodium borohydride and then 
treating with pyridine and iodomethane in methanol to afford the 
dimethyl derivative (70). 
 
 
  
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis route to access dithiol derivative (69) and dimethyl 
derivative (70). Reagents and conditions: a) i) NaBH4 ii) pyridine, MeOH, 
MeI, 3h, 80 % over two steps. 
 
These two control compounds support our proposed mechanism 
of action with a limited amount of activity observed in the dithiol 
derivative (69) and no activity in the totally blocked dimethyl 
derivative (70) (Table 3). 
 
Table 3. Results of FIV and cytotoxicity screening of 65 and 70  
 
Compound CrFKa CC50
b  EC50
b 
Number Viability  µM µM 
69 >100 15 1.8 
70 96 >100 >100 
aSample concentration of compound in CrFK cells at 10 μM (% Viability); 
bGeometric mean, each concentration tested in triplicate after 7 days as a 
difference of the untreated cells. 
 
Conclusions 
 
     The nanomolar potencies of these compounds coupled with 
light toxicities are a significant step forward in the design and 
utilization of the ETP scaffold as a functional series beyond 
generic toxicity. This is only the second report of reduced 
toxicity with the ETP core by structural simplification.37 
Highlighting that this core has the potential for versatile 
applications beyond cancer. This is also an indication that the 
zinc abstraction mechanism and/or the ETP core does not 
automatically equate to a toxic pharmacophore. The therapeutic 
index of the ester containing compounds (38-40) was particularly 
encouraging and highlights the need for more investigation of 
this privileged core. These focused libraries demonstrate there is 
scope for optimization and possibly development of a candidate 
compound for targeting the FIV/HIV nucleocapsid protein. The 
ETP functionality while relatively under-explored has the 
potential to generate a pre-clinical candidate that can treat both 
FIV and HIV in an in-vivo setting.  
 
Chemistry  
 
General chemistry section 
 
     All reactions requiring the use of dry conditions were carried 
out under an atmosphere of nitrogen and all glassware was pre-
dried in an oven (110 °C) and cooled under nitrogen prior to use. 
Stirring was by internal magnetic follower unless otherwise 
stated. Microwave heated reactions were carried out in a 
Biotage™ Initiator 2.5. All reactions were followed by TLC and 
organic phases extracted were dried with anhydrous magnesium 
sulfate or sodium sulfate as required. TLC analysis was carried 
out using Merck aluminium-backed plates coated with silica gel 
60 F254. Components were visualised using combinations of 
ultraviolet light, iodine and ceric ammonium molybdate stain. All 
anhydrous solvents and reagents were purchased from Sigma-
Aldrich and Fisher Scientific and used with Oxford sure/seal 
valves attached to a standard Schlenk line for solvent removal.  
 
     Purification of compounds was carried out using two different 
methodologies: flash column chromatography (FCC) as reported 
by Still et al or by automatic column chromatography (ACC).38 
Silica gel used for FCC was Merck 60 (230-400 mesh). ACC was 
carried out using a Biotage™ Horizon High Performance Flash 
Chromatography (HPFC). The use of this automated system 
required different pre-packed silica columns supported by the 
system and supplied by Biotage™. Columns used were: Flash 
12+S, Flash 12+M, Flash 25+S, Flash 25+M, SNAP 10 g, SNAP 
25 g, SNAP 50 g, SNAP 100 g, ZIP 5 g, ZIP 10 g, ZIP 30 g and 
ZIP 45 g cartridges.  
 
     Infrared spectra were recorded on a Bruker Alpha FT-IR 
spectrophotometer using NaCl plates. 1H NMR and 13C NMR 
were recorded using either a Bruker AM400 spectrometer 
operating at 400 MHz for proton and 101 MHz for carbon or a 
Bruker AM500 spectrometer operating at 500 MHz for proton 
and 126 MHz for carbon. Chemical shifts (H and C) are quoted 
as parts per million downfield from 0. The multiplicity of a 1H 
NMR signal is designated by one of the following abbreviations: 
s = singlet, d = doublet, t = triplet, q = quartet, br = broad and m 
= multiplet. Coupling constants (J) are expressed in Hertz. High-
resolution mass spectra were carried out using either a Kratos 
MS89MS with Kratos DS90 software or a Jeol AX505W with 
Jeol complement data system. Samples were ionised 
electronically (EI), with an accelerating voltage of 6kV or by 
low-resolution fast atom bombardment (FAB) in a thioglycerol 
matrix.  High-resolution fast atom bombardment was carried out 
at the ULIRS mass spectrometry facility at UCL School of 
Pharmacy. 
 
General method formation of 17, 18 and 46 
 
Amine (25.2 mmol) was added to a solution of ethyl glyoxalate 
(5.0 mL of a 50% solution in toluene, 25.2 mmol) in toluene 
(20.0 mL) at room temperature (RT) and stirred for 2 minutes, 
whereupon para-methoxybenzyl mercaptan (25.2 mmol) was 
added and the mixture stirred for 2 hours. Solvent was removed 
under reduced pressure and the residue purified via Biotage™ 
Horizon to give the desired amide (17, 18 and 46). 
 
General method formation of 19, 20 and 47 
 
A solution of 2-chloro-2-oxoethane-1,1-diyl diacetate (26.3 
mmol) in dichloromethane (20.0 mL) was added dropwise to a 
rapidly stirred biphasic mixture of previously synthesised amide 
(21.9 mmol) and sodium hydrogen carbonate (153 mmol) in 
dichloromethane (150 mL) and water (100 mL) at RT and the 
resulting mixture stirred rapidly for 12 hours. The layers were 
separated and the aqueous phase extracted with dichloromethane 
(2 x 100 mL). The combined extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure to give 
desired diacetate amide intermediate that did not require further 
purification (19, 20 and 47). 
 
 
 
 
General method formation of 21-32 
 
Amine (1.58 mmol) was added to a solution of the diacetate 
amide intermediate (0.53 mmol) in acetonitrile (15.0 mL) 
followed by addition para-methoxybenzyl mercaptan (0.79 
mmol) and the resulting mixture stirred for 2 minutes. DMAP 
(0.26 mmol) was added and the resulting mixture heated at reflux 
for 16 hours, cooled to RT and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon and, 
when possible, recrystallised to give the desired diketopiperazine 
(21-32). 
 
General method formation of 33-44, 62-65 and 67 
 
Boron tribromide (0.56 mmol) was added dropwise to a solution 
of the diketopiperazine (0.28 mmol) in dichloromethane (10.0 
mL) at -78 °C. The resulting mixture was stirred for 30 minutes 
whereupon sodium hydrogen carbonate (10.0 mL of a saturated 
aqueous solution) was added and the biphasic mixture stirred for 
15 minutes until the yellow colour had dissipated. The resulting 
mixture was stirred at room temperature for 40 minutes, 
whereupon iodine was added portionwise until the colour due to 
iodine just persisted and stirring was maintained for 5 minutes. A 
solution of saturated aqueous sodium thiosulfate was added and 
the mixture stirred for 30 minutes, diluted with dichloromethane 
(10.0 mL) and water (20.0 mL). The layers were separated and 
the aqueous phase extracted with dichloromethane (2 x 20.0 mL). 
The combined organic extracts were dried over MgSO4, filtered 
and solvent removed under reduced pressure. The residue was 
purified via Biotage™ Horizon and, when possible, recrystallized 
(ethyl acetate/hexane) to give the desired 
epidithiodiketopiperazines (33-44 and 62-65). 
 
Characterization of 33 – 44 
 
(±)-(1S,4S)-2,5-Dimethyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (33) Pale 
yellow solid (70 mg, 68%); m.p. 202-205 C; IR: max/cm-1 1686 
(C=O), 1390 (CH3);  H (400 MHz; CDCl3) 3.05 (6H, s, NCH3), 
5.15 (2H, s, CHS);  C (101 MHz, CDCl3) 31.59 (NCH3), 67.60 
(CHS), 164.32 (CO); m/z 202 (100%, [M-H]-): Found [M-H]- 
202.9957, C6H7N2O2S2 requires 202.9949. Consistent with 
previous report.39 
 
(±)-(1S,4S)-2-Benzyl-5-methyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (34) Pale 
yellow solid (70 mg, 65%); m.p. 109-111 C; IR: max/cm-1 1699 
(C=O);  H (400 MHz; CDCl3) 3.12 (3H, s, NCH3), 4.49 (1H, d, 
J 12.9, NCH2), 4.90 (1H, d, J 12.9, NCH2), 5.20 (1H, s, CHS), 
5.32 (1H, s, CHS), 7.28 – 7.39 (5H, m, Ar-H);  C (101 MHz, 
CDCl3) 31.4 (NCH3), 47.5 (CH2), 64.3 (CHS), 67.5 (CHS), 
128.4 (Ar-C-H), 128.6 (Ar-C-H), 129.2 (Ar-C-H), 134.0 
(quaternary C), 163.9 (CO), 164.0 (CO); m/z 281 (100%, 
[M+H]+): Found [M+H]+ 281.0415, C12H13N2O2S2 requires 
281.0418. Consistent with previous report.23a 
 
(±)-(1S,4S)-2-Benzyl-5-butyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (35) Pale 
yellow solid (80 mg, 54%); m.p. 119-121 C; IR: max/cm-1 1681 
(C=O);  H (400 MHz; CDCl3) 0.95 (3H, t, J 7.3, 
NCH2(CH2)2CH3), 1.29 – 1.37 (2H, m, NCH2(CH2)2CH3), 1.61 – 
1.72 (2H, m, NCH2(CH2)2CH3), 3.42 – 3.59 (2H, m, 
NCH2(CH2)2CH3), 4.51 (1H, d, J 14.9, NCH2-Ph), 4.84 (1H, d, J 
14.9, NCH2-Ph), 5.18 (1H, s, CHS), 5.34 (1H, s, CHS), 7.26 – 
7.29 (2H, m, Ar-H), 7.31 – 7.38 (3H, m, Ar-H);  C (101 MHz; 
CDCl3) 13.7 (CH3), 19.9 (CH2), 29.8 (CH2), 44.9 (CH2), 47.7 
(CH2), 64.7 (CHS), 65.6 (CHS), 128.4 (Ar-C-H), 128.6 (Ar-C-
H), 129.1 (Ar-C-H), 134.1 (quaternary C), 163.5 (CO), 164.0 
(CO); m/z 323 (100%, [M+H]+): Found [M+H]+ 323.0900, 
C15H19N2O2S2 requires 323.0888. Consistent with previous 
report.23a 
 
(±)-(1S,4S)-2-Benzyl-5-isopropyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (36) Pale 
yellow solid (40 mg, 65%); m.p. 177-180 C; IR: max/cm-1 1662 
(C=O), 1609 (C=C), 1434 (C-H), 731 (C-H);  H (400 MHz; 
CDCl3) 1.35 (6H, dd, J 12.9 & 6.8, CH(CH3)2), 1.61 (1H, s, 
CH(CH3)2), 4.53 (1H, d, J 12.6, NCH2-Ph), 4.83 (1H, d, J 12.9, 
NCH2-Ph), 5.19 (1H, s, CHS), 5.48 (1H, s, CHS), 7.30 (3H, d, J 
10.0, Ar-H), 7.39 (2H, d, J 7.4, Ar-H);  C (101 MHz, CDCl3) 
19.8 (CH3), 20.7 (CH3), 46.6 (CH), 48.0 (CH2), 61.0 (CHS), 65.3 
(CHS), 128.6 (Ar-C-H), 128.8 (Ar-C-H), 129.3 (Ar-C-H), 134.4 
(quaternary C), 163.0 (CO), 164.3 (CO); m/z 331 (100%, 
[M+Na]+): Found [M+Na]+ 331.0569, C14H16N2O2S2Na requires 
331.0551. Consistent with previous report.23a 
 
(±)-(1S,4S)-2-Allyl-5-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (37) Pale 
yellow solid (30 mg, 60%); m.p. 116-118 C; IR: max/cm-1 1685 
(C=O);  H (400 MHz; CDCl3) 3.96 (1H, dd, J 15.4 & 8.6, 
NCH2CH=CH2), 4.25 (1H, dd, J 15.4 & 7.6, NCH2CH=CH2), 
4.49 (1H, d, J 11.7, NCH2), 4.85 (1H, d, J 11.9, NCH2), 5.22 (1H, 
s, CHS), 5.33 – 5.34 (2H, m, CH=CH2), 5.36 (1H, s, CHS), 5.38 
– 5.42 (1H, m, CH=CH2), 7.26 – 7.29 (2H, m, Ar-H), 7.32 – 7.39 
(3H, m, Ar-H);  C (101 MHz, CDCl3) 46.4 (CH2), 47.5 (CH2), 
64.4 (CHS), 64.6 (CHS), 120.7 (CHCH2), 128.3 (Ar-C-H), 128.5 
(Ar-C-H), 129.1 (Ar-C-H), 130.7 (CH=CH2), 134.1 (quaternary 
C), 163.4 (CO), 163.8 (CO); m/z 307 (100%, [M+H]+): Found 
[M+H]+ 307.0484, C14H15N2O2S2 requires 307.0497. Consistent 
with previous report.18a  
 
(±)-(1S,4S)-2,5-Dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (38) Pale 
yellow solid (100 mg, 85%); m.p. 166-188 C; IR: max/cm-1 1685 
(C=O);  H (400 MHz; CDCl3) 4.63 (2H, d, J 12.0, CH2Ar), 4.99 
(2H, d, J 12.0 Hz, CH2Ar), 5.39 (2H, s, CHS), 7.40 – 7.54 (10H, 
m, Ar-H);  C (101 MHz, CDCl3) 48.1 (CH2), 65.1 (CH), 128.85 
(Ar-C-H), 129.0 (Ar-C-H), 129.6 (Ar-C-H), 134.5 (quaternary 
C), 164.2 (CO); m/z 357 (100%, [M+H]+): Found [M+H]+ 
357.0651, C18H17N2O2S2 requires 357.0653. Consistent with 
previous report.23a 
 
(±)-(1S,4S)-2-Benzyl-5-(3-chlorobenzyl)-7-thia-2,5-
diazabicyclo [2.2.1]heptane-3,6-dione 7-sulfide (39) Pale 
yellow solid (140 mg, 32%); m.p. 147-149 C; IR: max/cm-1 1674 
(C=O);  H (400 MHz; CDCl3) 4.50 – 4.52 (2H, m, NCH2Ar), 
4.72 (1H, d, J 11.1, NCH2), 4.84 (1H, d, J 11.9, NCH2), 5.26 (1H, 
s, CHS), 5.27 (1H, s, CHS), 7.18 – 7.19 (1H, m, Ar-H), 7.26 – 
7.40 (8H, m, Ar-H);  C (101 MHz, CDCl3) 47.2 (NCH2), 47.7 
(NCH2), 64.5 (CHS), 64.9 (CHS), 126.3 (Ar-C-H), 128.4 (Ar-C-
H), 128.4 (Ar-C-H), 128.6 (Ar-C-H), 128.7 (Ar-C-H), 129.1 (Ar-
C-H), 130.4 (Ar-C-H), 134.0 (quaternary C), 134.9 (quaternary 
C), 136.3 (quaternary C), 163.6 (CO), 163.7 (CO); m/z 391.0853 
(100%, [M+H]+), 392.0931 (27.6%, [M+H]+), 393.0873 (42.3%, 
[M+H]+), 394.0934 (14.1%, [M+H]+), 395.0991 (13.9%, 
[M+H]+), C18H16ClN2O2S2 requires 391.0842. Consistent with 
previous report.23a 
 
(±)-(1S,4S)-2-Benzyl-5-(4-methoxybenzyl)-7-thia-2,5-
diazabicyclo[2.2.1] heptane-3,6-dione 7-sulfide (40) Pale 
yellow solid (110 mg, 48%); m.p. 146-148 C; IR: max/cm-1 2991 
(C-H), 1681 (C=O);  H (400 MHz; CDCl3) 3.80 (3H, s, OCH3), 
4.43 (1H, d, J 12.7, CH2), 4.48 (1H, d, J 13.0, CH2), 4.75 (1H, d, 
J 12.7, CH2), 4.82 (1H, d, J 13.0, CH2), 5.25 (1H, s, CHS), 5.26 
(1H, s, CHS), 6.90 (2H, d, J 8.6, Ar-H), 7.21 (2H, d, J 8.6, Ar-
H), 7.27 – 7.29 (2H, m, Ar-H), 7.35 – 7.36 (3H, m, Ar-H);  C 
(101 MHz, CDCl3) 47.1 (CH2), 47.6 (CH2), 55.2 (OCH3), 64.3 
(CHS), 64.7 (CHS), 114.5 (Ar-C-H), 100.8 (quaternary C), 128.3 
(Ar-C-H), 128.5 (Ar-C-H), 129.1 (Ar-C-H), 129.9 (Ar-C-H), 
134.1 (quaternary C), 159.7 (quaternary C), 163.6 (CO), 163.8 
(CO); m/z 387 (100%, [M+H]+): Found [M+H]+ 387.0833, 
C19H19N2O3S2 requires 387.0837. Consistent with previous 
report.23a 
 
Ethyl 3-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo [2.2.1]heptan-2-yl)propanoate (41) Pale yellow 
solid (50 mg, 51%); m.p. 100-104 C; max/cm-1 1670 (C=O), 
1496 (C-H);  H (400 MHz; CDCl3) 1.30 (3H, t, J 7.1, 
OCH2CH3), 2.71 (2H, t, J 6.2, NCH2), 3.79 – 3.84 (2H, m, 
NCH2CH2), 4.22 (2H, q, J 7.1, OCH2CH3), 4.50 (1H, d, J 15.0, 
NCH2), 4.86 (1H, d, J 15.0, NCH2), 5.19 (1H, s, CHS), 5.67 (1H, 
s, CHS), 7.28 – 7.29 (1H, m, Ar-H), 7.30 (1H, d, J 2.0, Ar-H), 
7.38 (2H, t, J 2.1, Ar-H), 7.39 – 7.40 (1H, m, Ar-H);  C (101 
MHz; CDCl3) 14.4 (CH3), 33.0 (CH2), 41.9 (CH2), 47.9 (CH2), 
61.5 (CH2), 64.8 (CHS), 67.0 (CHS), 128.6 (Ar-C-H), 128.8 (Ar-
C-H), 129.4 (Ar-C-H), 134.5 (quaternary C), 163.6 (CO), 164.1 
(CO), 171.7 (CO); m/z 389 (100%, [M+Na]+): Found [M+Na]+ 
389.0622, C16H18N2O4S2Na requires 389.0606. Consistent with 
previous report.23a  
 
Methyl 6-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo[2.2.1]heptan-2-yl)hexanoate (42) Pale yellow 
solid (70 mg, 75%);  m.p. 85-88 C; IR: max/cm-1 2933 (C-H), 
1734 (C=O), 1674 (C=O), 1451 (CH2), 733 (C-H);  H (400 
MHz; CDCl3) 1.36 – 1.42 (2H, m, NCH2(CH2)3CH2CO), 2.34 
(2H, t, J 7.4, NCH2(CH2)3CH2CO), 3.53 (2H, t, J 7.3, 
NCH2(CH2)3CH2CO), 3.68 – 3.69 (5H, m, CH2CO2CH3), 3.73 – 
3.80 (2H, m, NCH2(CH2)3CH2CO), 4.52 (1H, d, J 12.0, NCH2-
Ph), 4.85 (1H, d, J 12.0, NCH2-Ph), 5.20 (1H, s, CHS), 5.37 (1H, 
s, CHS), 7.30 (2H, d, J 7.7, Ar-H), 7.37 – 7.40 (3H, m, Ar-H);  
C (101 MHz, CDCl3) 24.6 (CH2), 26.3 (CH2), 27.6 (CH2), 34.0 
(CH2), 45.3 (CH2), 47.9 (CH2), 51.7 (CH3), 64.9 (CHS), 65.8 
(CHS), 128.6 (Ar-C-H), 128.8 (Ar-C-H), 129.3 (Ar-C-H), 134.3 
(quaternary C), 163.8 (CO), 164.2 (CO), 174.0 (CO); m/z 417 
(100%, [M+Na]+): Found [M+Na]+ 417.0939, C18H22N2O4S2Na 
requires 417.0919. Consistent with previous report.23a 
 
Ethyl 4-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo [2.2.1]heptan-2-yl)butanoate (43) Pale yellow 
solid (50 mg, 64%); m.p. 82-84 C; IR: max/cm-1 1498 (CH2), 
1160 (C-C(O)-C);  H (400 MHz; CDCl3) 1.28 (3H, t, J 7.1, 
OCH2CH3), 1.99 – 2.09 (2H, m, NCH2CH2CH2CO), 2.40 – 2.43 
(2H, m, NCH2CH2CH2CO), 3.52 – 3.67 (2H, m, 
NCH2CH2CH2CO), 4.17 – 4.20 (2H, m, OCH2CH3), 4.53 (1H, d, 
J 12.0, NCH2-Ph), 4.86 (1H, d, J 12.2, NCH2-Ph), 5.20 (1H, s, 
CHS), 5.42 (1H, s, CHS), 7.29 – 7.32 (2H, m, Ar-H), 7.36 – 7.41 
(3 H, m, Ar-H);  C (101 MHz, CDCl3) 14.4 (CH3), 23.3 (CH2), 
31.2 (CH2), 44.9 (CH2), 48.0 (CH2), 60.9 (CH2), 64.9 (CHS), 
66.1 (CHS), 128.7 (Ar-C-H), 128.8 (Ar-C-H), 129.4 (Ar-C-H), 
134.3 (quaternary C), 163.9 (CO), 164.1 (CO), 172.7 (CO); m/z 
403 (100%, [M+Na]+): Found [M+Na]+ 403.1341, 
C17H20N2O4S2Na requires 403.0762. Consistent with previous 
report.23a 
 
(±)-(1S,4S)-2-Benzyl-5-(naphthalen-1-ylmethyl)-7-thia-2,5-
diazabicyclo [2.2.1]heptane-3,6-dione 7-sulfide (44) Pale 
yellow solid (180 mg, 85%); m.p. 161-163 C; IR: max/cm-1 1685 
(C=O);  H (400 MHz; CDCl3) 4.40 (1H, d, J 12.6, NCH2), 4.79 
– 4.84 (3H, m, NCH2), 5.24 (1H, s, CHS), 5.30 (1H, s, CHS), 
7.20 – 7.25 (2H, m, Ar-H), 7.34 – 7.39 (3H, m, Ar-H), 7.44 – 
7.47 (2H, m, Ar-H), 7.53 – 7.58 (2H, m, Ar-H), 7.88 – 7.92 (2H, 
m, Ar-H), 7.95 – 8.00 (1H, m, Ar-H);  C (101 MHz, CDCl3) 
45.1 (CH2), 47.3 (CH2), 63.4 (CHS), 64.6 (CHS), 123.1 (Ar-C-
H), 100.1 (Ar-C-H), 126.3 (Ar-C-H), 126.9 (Ar-C-H), 128.1 (Ar-
C-H), 128.4 (Ar-C-H), 128.4 (Ar-C-H), 128.8 (Ar-C-H), 129.0 
(Ar-C-H), 129.5 (quaternary C), 129.9 (Ar-C-H), 131.5 
(quaternary C), 133.8 (quaternary C), 134.1 (quaternary C), 
163.4 (CO), 163.5 (CO); m/z 407 (100%, [M+H]+): Found 
[M+H]+ 407.0791, C22H19N2O2S2 requires 407.0810. Consistent 
with previous report.23a 
 
General Method formation of 48 - 51 
 
Amine (1.93 mmol) was added to a solution of previously 
synthesised diacetate amide intermediate (1.29 mmol) in 
methanol (15.0 mL) and the resulting mixture stirred for 2 
minutes. DMAP (0.64 mmol) was added and the resulting 
mixture was stirred for 5 hours at RT and solvent removed under 
reduced pressure. The residue was purified via Biotage™ 
Horizon and recrystallised to give the desired methoxy 
intermediate (48-51). 
 
General Method formation of 52 - 56 
 
LiHMDS (1M solution in tetrahydrofuran, 0.34 mmol) was added 
dropwise to a solution of the previously synthesised methoxy 
intermediate (0.17 mmol) and halogenoalkane (0.84 mmol) in 
tetrahydrofuran (2.00 mL) at -78 °C and the resulting mixture 
was stirred at this temperature for 1 hour and 1.5 hours at 0 °C. 
Saturated aqueous sodium hydrogen carbonate (10.0 mL) was 
added and solvent removed under reduced pressure. The residue 
was partitioned between water (10.0 mL) and dichloromethane 
(20.0 mL). The aqueous phase was extracted with 
dichloromethane (2 x 10.0 mL) and the combined extracts were 
dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon to give 
the desired tri-substituted methoxy intermediate (42-57). 
 
General Method formation of 57 - 61 
 
TFA (9.17 mmol) was added to a solution of tri-substituted 
methoxy intermediate (0.61 mmol) in dichloromethane (10.0 mL) 
at RT followed by the addition of para-methoxybenzyl 
mercaptan (0.92 mmol) and the resulting mixture was stirred at 
this temperature for 18 hours. After, the solution was diluted in 
dichloromethane (10.0 mL) and washed with saturated aqueous 
sodium hydrogen carbonate (10.0 mL). The aqueous phase was 
extracted with dichloromethane (2 x 10.0 mL) and the combined 
extracts were dried (MgSO4), filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ 
Horizon and recrystallised (ethyl acetate/hexane) to give the 
desired diketopiperazine (58-63). 
 
Method formation of 66 
 
LiHMDS (1M solution in tetrahydrofuran, 0.68 mmol) was added 
dropwise to a solution of 61 (0.17 mmol) and allyl bromide (1.68 
mmol) in tetrahydrofuran (2.0 mL) at -78 °C and the resulting 
mixture was stirred at this temperature for 1 hour and 1.5 hours at 
0 °C. Saturated aqueous sodium hydrogen carbonate (10.0 mL) 
was added and solvent removed under reduced pressure. The 
residue was partitioned between water (10.0 mL) and 
dichloromethane (20.0 mL). The aqueous phase was extracted 
with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon to give 
66. 
 
Method formation of 67 
 
Boron tribromide (0.56 mmol) was added dropwise to a solution 
of 66 (0.28 mmol) in dichloromethane (10.0 mL) at -78 °C. The 
resulting mixture was stirred for 30 minutes whereupon sodium 
hydrogen carbonate (10.0 mL of a saturated aqueous solution) 
was added and the biphasic mixture stirred for 15 minutes until 
the yellow colour had dissipated. The resulting mixture was 
stirred at room temperature for 40 minutes, whereupon iodine 
was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 5 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture 
stirred for 30 minutes, diluted with dichloromethane (10.0 mL) 
and water (20.0 mL). The layers were separated and the aqueous 
phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and 
solvent removed under reduced pressure. The residue was 
purified via Biotage™ Horizon to give 67. 
 
Characterization of 62 – 65, 67 and 69 – 70 
 
(±)-(1S,4S)-5-Allyl-1,2-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (62) Pale 
yellow solid (0.19 g, 23%); m.p. 62-64 °C; max/cm-1 1685 
(C=O), 1628 (C=C), 734 (C-H), 697 (C-H);  H (400 MHz, 
CDCl3) 3.84 (2H, s, CH2-Ph), 3.86 – 3.90 (1H, m, 
NCH2CH=CH2), 4.00 – 4.05 (1H, m, NCH2CH=CH2), 4.09 (1H, 
d, J 15.0, NCH2-Ph), 4.64 (1H, s, CHS), 4.75 (1 H, d, J 17.1, 
CH=CH2), 5.03 (1H, d, J 17.1, CH=CH2), 5.22 (1H, d, J 15.0, 
NCH2-Ph), 5.55 – 5.67 (1H, m, CH=CH2), 6.89 – 6.92 (4H, m, 
Ar-H), 7.36 – 7.42 (6H, m, Ar-H);  C (101 MHz, CDCl3) 35.9 
(CH2), 46.1 (CH2), 48.0 (CH2), 55.6 (CHS), 59.3 (CH=CH2), 
114.4 (Ar-C-H), 119.5 (CH=CH2), 123.9 (Ar-C-H), 127.7 (Ar-C-
H), 128.7 (Ar-C-H), 129.7 (Ar-C-H), 130.8 (Ar-C-H), 134.0 
(quaternary C), 136.5 (quaternary C), 159.4 (quaternary C), 
163.6 (CO), 165.7 (CO); m/z 397 (100%, [M+H]+); Found 
[M+H]+ 397.1078, C21H21N2O2S2 requires 397.1045. 
 
(±)-(1S,4S)-1-Allyl-2,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (63) Pale 
yellow solid (0.13 g, 24%); m.p. 63-65 °C; max/cm-1 1687 (C=O, 
C=C), 1453 (CH2), 730 (C-H), 697 (C-H);  H (400 MHz, 
CDCl3) 3.07 – 3.14 (1H, m, CH2CH=CH2), 3.25 – 3.31 (1H, m, 
CH2CH=CH2), 4.53 – 4.58 (1H, m, NCH2-Ph), 4.63 – 4.68 (1H, 
m, NCH2-Ph), 4.95 (1H, d, J 15.9, NCH2-Ph), 5.13 (1H, d, J 16.1, 
NCH2-Ph), 5.28 – 5.35 (2H, m, CH=CH2), 5.41 (1H, s, CHS), 
6.16 – 6.20 (1H, m, CH=CH2), 7.27 – 7.30 (3H, m, Ar-H), 7.32 – 
7.36 (4H, m, Ar-H), 7.39 – 7.43 (3H, m, Ar-H);  C (101 MHz, 
CDCl3) 36.4 (CH2), 45.4 (CH2), 48.7 (CH2), 64.2 (CHS), 75.2 
(quaternary C), 120.9 (CH2), 127.1 (Ar-C-H), 128.0 (Ar-C-H), 
128.7 (Ar-C-H), 128.7 (Ar-C-H), 128.9 (Ar-C-H), 129.3 (Ar-C-
H), 131.6 (CH=CH2), 134.5 (quaternary C), 136.1 (quaternary 
C), 164.6 (CO), 165.1 (CO); m/z 419 (100%, [M+Na]+); Found 
[M+Na]+ 419.0852, C21H20N2O2S2Na requires 419.0864. 
 
(±)-(1S,4S)-2-Allyl-1,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (64) Pale 
yellow solid (0.38 g, 21%); m.p. 63-64 °C; max/cm-1 1672 
(C=O), 1627 (C=C), 832 (C-H), 698 (C-H);  H (400 MHz, 
CDCl3) 3.84 (2H, s, CH2-Ph), 3.87 – 3.91 (2H, m, 
NCH2CH=CH2), 4.04 (1H, d, J 6.9, NCH2-Ph), 4.65 (1H, s, 
CHS), 4.73 (1H, d, J 10.1, CH=CH2), 5.04 (1H, d, J 10.0, 
CH=CH2), 5.21 (1H, d, J 7.1, NCH2-Ph), 5.56 – 5.70 (1H, m, 
CH=CH2), 6.85 – 6.90 (2H, m, Ar-H), 6.91 – 6.97 (4H, m, Ar-H), 
7.37 – 7.40 (4H, m, Ar-H);  C (101 MHz, CDCl3) 44.0 (CH2), 
46.0 (CH2), 47.9 (CH2), 55.5 (CHS), 59.3 (CH=CH2), 119.4 
(CH=CH2), 123.9 (Ar-C-H), 127.6 (Ar-C-H), 128.7 (Ar-C-H), 
128.8 (Ar-C-H), 129.6 (Ar-C-H), 130.7 (Ar-C-H), 133.9 
(quaternary C), 136.4 (quaternary C), 159.3 (quaternary C), 
163.5 (CO), 165.6 (CO); m/z 419 (100%, [M+Na]+); Found 
[M+Na]+ 419.0973, C21H20N2O2S2Na requires 419.0864. 
 
(±)-(1S,4S)-1,2-Diallyl-5-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (65) Pale 
yellow oil (0.27 g, 28%); max/cm
-1 1674 (C=O), 1609 (C=C), 
833 (C-H), 735 (C-H), 701 (C-H);  H (400 MHz, CDCl3) 3.23 – 
3.29 (1H, m, CH2CH=CH2), 3.90 – 3.99 (1H, m, CH2CH=CH2), 
4.41 – 4.48 (2H, m, NCH2), 4.82 (1H, d, J 14.9, NCH2), 5.15 
(1H, d, J 14.5, NCH2), 5.21 (1H, s, CHS), 5.22 – 5.27 (2H, m, 
CH=CH2), 5.30 – 5.33 (2H, m, CH=CH2), 5.76 – 5.85 (1H, m, 
CH=CH2), 6.07 – 6.12 (1H, m, CH=CH2), 7.21 – 7.24 (2H, m, 
Ar-H), 7.27 – 7.31 (3H, m, Ar-H);  C (101 MHz, CDCl3) 36.2 
(CH2), 45.0 (CH2), 48.6 (CH2), 64.3 (CHS), 75.3 (quaternary C), 
118.2 (CH2), 120.8 (CH2), 128.7 (CH), 128.7 (Ar-C-H), 129.3 
(CH), 131.7 (Ar-C-H), 131.9 (Ar-C-H), 134.5 (quaternary C), 
164.5 (CO), 164.7 (CO); m/z 369 (100%, [M+Na]+); Found 
[M+Na]+ 369.0726, C17H18N2O2S2Na requires 369.0707. 
 
(±)-(1S,4S)-1,2,4,5-Tetraallyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (67) White solid 
(0.10 g, 41%); m.p. 180-182 °C; max/cm-1 1639 (C=O, C=C), 
1462 (CH2), 749 (CH2);  H (400 MHz, CDCl3) 3.20 – 3.27 (2H, 
m, CH2CH=CH), 3.28 – 3.36 (2H, m, CH2CH=CH), 4.04 (2H, 
dd, J 16.4 & 6.8, NCH2), 4.62 (2H, dd, J 16.2 & 4.8, NCH2), 5.21 
– 5.41 (8H, m, CH=CH2), 5.89 – 5.94 (2H, m, CH=CH2), 6.12 – 
6.17 (2H, m, CH=CH2);  C (101 MHz, CDCl3) 36.4 (CH2), 45.5 
(CH2), 74.5 (quaternary C), 118.3 (CH=CH2), 120.6 (CH=CH2), 
131.7 (CH=CH2), 132.0 (CH=CH2), 165.0 (CO); m/z 337 (100%, 
[M+H]+); Found [M+H]+ 337.1456, C16H21N2O2S2 requires 
337.1448. 
 
(3S,6S)-1,4-Dibenzyl-3,6-dimercaptopiperazine-2,5-dione (69) 
Prepared as previously described.18a m.p. 150-152 °C; IR: 
max/cm-1 2504.4, 1660.6, 1430.1, 1254.6;  H (300 MHz, 
CDCl3) 2.98 (d, J = 7.0 Hz, 2H), 4.08 (d, J = 14.5 Hz, 2H), 4.88 
(d, J = 7 Hz, 2H), 5.17 (d, J = 14.5 Hz, 2H), 7.16-7.31 (m, 10H); 
 C (75 MHz; CDCl3) 47.9, 56.2, 129.0, 129.1, 129.6, 134.6, 
165.1; HRMS (m/z): [M +Na]+ calcd. for C18H18N2NaO2S2, 
381.0702; found, 381.0700. Consistent with previous report.18a 
 
cis-1,4-Dibenzyl-3,6-bis(methylthio)piperazine-2,5-dione (70) 
Sodium borohydride (0.07 g, 1.80 mmol) was added portionwise 
over 30 minutes to a stirred solution of disulfide (38) (0.32 g, 
0.90 mmol). Iodomethane (2 mL) in pyridine (3 mL) and 
methanol (5 mL) were added to the resultant mixture and stirred 
for 30 minutes where upon a further portion of iodomethane (3 
mL) was added and the reaction and stirred for 2 hours. The 
reaction mixture was poured into water (30 mL) and acidified 
with dilute aqueous hydrochloric acid (1 M) and extracted with 
dichloromethane (3 x 50 mL). The combined organic extracts 
were dried (MgSO4), filtered and solvent removed under reduced 
pressure. Purification by flash column chromatography (3: 1, 
petroleum spirit: ethyl acetate) gave the cis-protected 
dithiodiketopiperazine (70) as a colorless solid (0.28 g, 80%); 
m.p. 107-109 ºC; IR: max/cm-1 1674.1, 1429.2, 1169.5;  δ H (500 
MHz, CDCl3) δ 2.34 (s, 6H), 4.17 (d, J = 14.5 Hz, 2H), 4.54 (s, 
2H), 5.37 (d, J = 14.5 Hz, 2H), 7.40–7.30 (m, 10H); δ C (126 
MHz, CDCl3) 16.8, 47.0, 62.2, 128.4, 128.6, 129.1, 134.8, 164.3; 
 HRMS (m/z): [M]+ calcd. for C20H22N2NaO2S2, 409.1015; found, 
409.1014. Consistent with previous reports.18a,23c 
 
Molecular Modelling   
 
Molecular modelling was performed using Schrödinger suite 
2018-4 and comparative modelling was done using Biovia 
Discovery Studio Client. Structures of small molecules were 
prepared using the LigPrep module of Schrodinger Maestro 
(Schrödinger Inc., New York, NY, USA). The homology model 
of NCp7 was updated using NMR structure of Zn complex of 
EIAV NCp1 as template and the model is based on sequence 
alignment (PDB:2BL6) identity 50%, positive 70%, alignment 
length 34, E-value 1.88805e-08, resolution: NMR).8e The model 
was constructed using standard settings of Discovery Studio 
homology modelling protocol. Side chains of the active site 
residues were further refined using Prime module of Schrodinger. 
The final model was processed using the protein preparation 
wizard of Maestro in order to optimize hydrogen bonding 
network followed by short minimization using 0.3Å rmsd 
constraint for heavy atoms. Ligand structures were manually 
docked towards zinc finger motif using our previous models as 
template and geometry was further refined using “refine protein-
ligand complex” functionality embed in Schrodinger suite. 
Chemical Computing Group's Molecular Operating Environment 
(MOE v.2018.01) was used to study GRID type of interactions 
fields to find out if carbonyl oxygen has favorable interaction 
with zinc. 
 
DFT studies.  
 
DFT calculations and Fuikui f- functions were calculated using 
Jaguar module of Schrödinger Suite. Homology model based 
model compound composition was set up using Maestro software 
(Schrödinger Inc., New York, NY, USA). The geometry of zinc 
finger cysteines and histidines were constrained to their initial 
geometry using Cartesian constraints to connector carbon atoms. 
The density functional B3LYP of theory and MSV basis set were 
used for geometry optimizations in the gas phase using Jaguar 
module of Schrödinger suite. 
 
Fuikui Functions. 
 
Other than the zinc-finger mimic in the models, structures were 
geometry optimised using unconstrained gas phase geometry 
DFT using B3LYP theory and 6-31+G** basis. Fukui functions 
were computed as single point calculations with default Jaguar 
keywrods were used (basis=lacvp*+ dftname=b3lyp iacc=1 
dconv=5 x 10-6). The idea behind this is that nucleophilic atoms 
are those with large, negative values of f−. 
 
Biology Assays 
 
Cytotoxicity (CrFK and FL-4) and anti-viral FIV (FL-4) 
screening were performed as previously described.25c,40 
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